• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.

作者信息

Coplan P M, Noel R A, Levitan B S, Ferguson J, Mussen F

机构信息

Risk Management and Epidemiology, Purdue Pharma LP, Stamford, Connecticut, USA.

出版信息

Clin Pharmacol Ther. 2011 Feb;89(2):312-5. doi: 10.1038/clpt.2010.291. Epub 2010 Dec 15.

DOI:10.1038/clpt.2010.291
PMID:21160469
Abstract
摘要

相似文献

1
Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.建立一个提高药品效益风险平衡透明度、可重复性及沟通性的框架。
Clin Pharmacol Ther. 2011 Feb;89(2):312-5. doi: 10.1038/clpt.2010.291. Epub 2010 Dec 15.
2
Striking the right balance.把握恰当的平衡。
Nat Rev Drug Discov. 2006 Nov;5(11):879. doi: 10.1038/nrd2178.
3
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
4
Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.是否需要建立一个通用的药物获益-风险评估框架？监管和行业视角。
Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1004-12. doi: 10.1002/pds.3464. Epub 2013 Jun 5.
5
The identification of benefit in medical intervention: an overview and suggestions for process.医学干预中获益的识别：概述与流程建议
Am J Ther. 2008 Sep-Oct;15(5):495-503. doi: 10.1097/MJT.0b013e31816b8fff.
6
Communicating the risks of medicines: time to move forward.传达药品风险：是时候向前迈进了。
Med Care. 2012 Jun;50(6):463-5. doi: 10.1097/MLR.0b013e31825852f0.
7
[Communication and transparency concerning risk-benefit analysis in public health: the example of medication].公共卫生中风险效益分析的沟通与透明度：以药物为例
Therapie. 2001 Jul-Aug;56(4):335-9.
8
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
9
Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.药物安全问题的早期沟通：一项增强制药行业与监管机构互动的可行性研究。
Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):232-7. doi: 10.1002/pds.1898.
10
[Physician and pharmaceutical industry. II. Postmarketing surveillance].[医生与制药行业。II. 上市后监测]
Ned Tijdschr Geneeskd. 1992 Jan 4;136(1):36-41.

引用本文的文献

1
A proposal for using benefit-risk methods to improve the prominence of adverse event results when reporting trials.建议使用获益-风险方法来提高试验报告中不良事件结果的显著性。
Trials. 2024 Jun 22;25(1):409. doi: 10.1186/s13063-024-08228-0.
2
Key Opinion Leaders' Interviews to Inform the Future of Benefit-Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations.关键意见领袖访谈：为全球制药和医疗器械组织的医疗产品全生命周期的获益-风险规划的未来提供信息。
Drug Saf. 2024 Sep;47(9):853-868. doi: 10.1007/s40264-024-01442-4. Epub 2024 Jun 1.
3
A Structured Benefit-Risk Assessment Operating Model for Investigational Medicinal Products in the Pharmaceutical Industry.
制药行业研究用药品的结构化获益-风险评估操作模型。
Ther Innov Regul Sci. 2023 Jul;57(4):849-864. doi: 10.1007/s43441-023-00508-2. Epub 2023 Apr 1.
4
Multi-Criteria Decision Analysis for Benefit-Risk Analysis by National Regulatory Authorities.国家监管机构用于效益-风险分析的多标准决策分析
Front Med (Lausanne). 2022 Jan 12;8:820335. doi: 10.3389/fmed.2021.820335. eCollection 2021.
5
Comparative Benefit-Risk Assessment for Lidocaine 700 mg Medicated Plaster and Pregabalin in Peripheral Neuropathic Pain Following a Structured Framework Approach.基于结构化框架方法对700毫克利多卡因药用贴剂和普瑞巴林治疗外周神经性疼痛的比较获益-风险评估
Pain Ther. 2022 Mar;11(1):73-91. doi: 10.1007/s40122-021-00340-2. Epub 2021 Nov 18.
6
Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan.肺癌化疗属性的患者偏好：日本的离散选择实验研究
Front Pharmacol. 2021 Jul 20;12:697711. doi: 10.3389/fphar.2021.697711. eCollection 2021.
7
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework.儿童超适应证用药的获益-风险评估： Bravo 框架。
Clin Pharmacol Ther. 2021 Oct;110(4):952-965. doi: 10.1002/cpt.2336. Epub 2021 Jul 29.
8
Patient Global Impression of Benefit-Risk (PGI-BR): Incorporating Patients' Views of Clinical Benefit-Risk into Assessment of New Medicines.患者对获益-风险的整体评价（PGI-BR）：将患者对临床获益-风险的看法纳入新药评估。
Drug Saf. 2021 Oct;44(10):1059-1072. doi: 10.1007/s40264-021-01079-7. Epub 2021 Jun 15.
9
Psychosocial Factors Are Associated With Risk Acceptance in Upper Extremity Patients.心理社会因素与上肢患者的风险接受度相关。
Hand (N Y). 2022 Sep;17(5):988-992. doi: 10.1177/1558944720974123. Epub 2020 Dec 24.
10
Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.药品的结构化效益-风险评估：文献中定量效益-风险评估结果综述
Ther Adv Drug Saf. 2020 Dec 8;11:2042098620976951. doi: 10.1177/2042098620976951. eCollection 2020.